On December 31, 2025, Caring Brands, Inc. entered a license agreement with Itonis Pharmaceuticals to exclusively market and sell the Emesyl product, agreeing to pay an 8% royalty on sales and receive a 7% equity stake for every $200,000 in sales. The company must keep sales above $25,000 for four consecutive quarters to maintain exclusive rights.